Profluent Bio vs Umoja Biopharma

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (37 vs 41)
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile
Umoja Biopharma logo

Umoja Biopharma

EmergingBioTech

Cell Therapy

Umoja Biopharma raised $300M+ for its lentiviral vector CAR-T platform that delivers cancer-fighting T-cells in a single IV infusion, eliminating the need for cell extraction and manufacturing.

AI VisibilityBeta
Overall Score
C41
Category Rank
#2 of 2
AI Consensus
58%
Trend
up
Per Platform
ChatGPT
34
Perplexity
38
Gemini
40

About

Umoja Biopharma is developing an in vivo CAR-T cell therapy platform that circumvents the costly and time-consuming ex vivo manufacturing process that limits current CAR-T therapies. Instead of extracting a patient's T-cells, engineering them in a lab, and reinfusing them, Umoja's approach delivers viral vectors intravenously that reprogram T-cells directly inside the patient's body. This could reduce CAR-T therapy costs from $400,000+ to a fraction of that price.

Full profile

AI Visibility Head-to-Head

37
Overall Score
41
#1
Category Rank
#2
69
AI Consensus
58
up
Trend
up
45
ChatGPT
34
35
Perplexity
38
38
Gemini
40
37
Claude
50
31
Grok
32

Key Details

Category
AI Protein Design
Cell Therapy
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Profluent Bio
AI Protein Design
Only Umoja Biopharma
Cell Therapy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.